Managing the skin toxicities from new melanoma drugs.
Patients treated with ipilimumab or targeted inhibitors of the RAF-MEK-ERK pathway (vemurafenib, dabrafenib, and trametinib) for advanced cutaneous melanoma often experience drug-related skin toxicities denoted as dermatologic adverse events (DAEs). Although rarely life-threatening, DAEs may emerge...
| Publicado en: | Current Treatment Options in Oncology Vol. 15; no. 2; pp. 281 - 302 |
|---|---|
| Autores principales: | , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Jun2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |